1. Introduction {#s0005}
===============

Depression and anxiety disorders, due to their high prevalence, high disease burden, and common comorbidity ([@bb0100]; [@bb0105]; [@bb0375]; [@bb0390]; [@bb0550]; [@bb0625]), have been identified as two of the leading causes of disability ([@bb0040]; [@bb0305]) causing an enormous economic burden through, e.g. reduced workforce participation, occupational impairment, and lost productivity ([@bb0070]; [@bb0075]; [@bb0315]; [@bb0640]).

A variety of effective interventions for the treatment of common mental disorders (CMDs) have been developed over the past decades, and their efficacy has been demonstrated in a large number of randomized controlled trials (RCTs) ([@bb0180], [@bb0195]; [@bb0335]).

However, even though effective treatment modalities exist, most individuals in need of treatment for depression and anxiety remain untreated. What also adds to the unmet need for treatment, even when assuming the hypothetical scenario of 100% coverage and compliance to evidence-based treatments, is that only approximately one third of the disease burden attributable to MDD and half of the disease burden attributable to ADs could be averted with current treatments ([@bb0015]; [@bb0155]). For this reason, attention is increasingly focusing on prevention of CMDs, by targeting individuals before the onset of a full syndrome CMD ([@bb0280]).

Emerging evidence indicates the potential of disorder-specific interventions to prevent the development of MDD ([@bb0610]). However, evidence on the efficacy of interventions aiming to prevent the onset of anxiety especially long-term, is inconclusive. This is indicated by a meta-analysis showing that initial short-term effects diminish over time ([@bb0645]). Moreover, another general problem is the low likelihood that health care systems would implement and disseminate unique prevention programs for each single disorder. Also, MDD and ADs are highly comorbid ([@bb0055]), and risk factors and subclinical symptoms of depression and the different ADs overlap ([@bb0200]; [@bb0370]). Transdiagnostic concepts aiming at preventing the incidence of both conditions simultaneously may therefore show much promise ([@bb0030]; [@bb0105]). Transdiagnostic interventions that target a set of shared risk factors might increase the potential reach and impact of psychological prevention programs ([@bb0600]).

Comorbidities can also be targeted through individual tailoring which allows participants to receive individualized treatment protocols based on symptom profiles, preference, need, or characteristics ([@bb0010]; [@bb0485]). This also means that participants following a treatment protocol do not all receive the same standardized treatment.

However, evidence for the potential of transdiagnostic individually tailored concepts that target the prevention of MDD and ADs in adults, so far, is scarce. Only very few RCTs have been conducted that evaluated the effects of a psychological intervention on the onset of depression and anxiety disorders, and results have been mixed ([@bb0025]; [@bb0360]; [@bb0615]). In one study ([@bb0615]) the effectiveness of an indicated stepped-care prevention program of depression and anxiety disorders was evaluated in an at-risk elderly population and found the incidence rate halved in a 12-month follow-up. However, others ([@bb0025]) found no significant differences between a cognitive behavioral group intervention and the wait control group (WCG, information booklet) when considering the prevention of depression and anxiety in an at-risk population of pregnant women. Another study ([@bb0360]) testing the effectiveness of family meetings for at-risk family caregivers of dementia patients, found no superiority in preventing depression and anxiety disorders. In sum, more research is needed to investigate the potential of transdiagnostic psychological interventions for the prevention of MDD and ADs.

The previously mentioned limitations of conventional prevention programs could be overcome by utilizing internet- and mobile-based interventions, e.g. IMIs. Main advantages include: (1) accessibility: they are easily accessible at any time from any location via the internet, (2) anonymity: participation is anonymous so that stigmatization or self-disclosure in group settings can be avoided, (3) flexibility: participation can be completed at any individual speed, and materials can be reviewed as often as desired, (4) personalization: the intervention is adaptable and can be tailored to specific needs, and (5) treatment availability: affected individuals can be reached earlier than through traditional mental health services. Also, (6) scalability: IMIs are easily scalable, as by applying a small increase of therapeutic resources a greater proportion of the eligible population can be reached.

IMIs have already been shown to be effective in reducing symptoms of diverse psychological disorders, such as the treatment of depression ([@bb0245], [@bb0250]; [@bb0395]), anxiety ([@bb0185]; [@bb0450]; [@bb0480]), sleep disorders ([@bb0150]), eating disorders ([@bb0225]), or alcohol use disorders ([@bb0525]).

However, evidence of the effectiveness in preventing the incidence of CMDs through internet interventions in public health settings is still scarce; the latest systematic review identified ten RCTs that evaluated the effect of an IMI on CMD onset ([@bb0270], [@bb0275]). The only trial on the prevention of general anxiety did not result in significant positive findings ([@bb0160]). Of the three primary prevention trials aiming to reduce the incidence of a depressive disorder ([@bb0120]; [@bb0345]; [@bb0595]), only one trial ([@bb0120]; [@bb0260]) used standard diagnostic procedures, while the other two trials relied only on self-report questionnaires for onset identification. The aforementioned study by Buntrock, Ebert and colleagues ([@bb0110]) showed that internet-based guided self-help for the indicated prevention of depression (including at-risk individuals) can reduce symptoms of depression in adults with subthreshold depression ([@bb0115]) and reduce the risk of MDD onset by 39% within a year ([@bb0120]).

Even though it is often argued that internet-based interventions are likely to reduce the treatment costs, evidence from RCTs is still scarce and even completely absent when it comes to IMIs for the transdiagnostic prevention of both MDD and ADs. The only trial we are aware of evaluating cost-effectiveness of internet-based prevention is the trial from Buntrock and colleagues in which the authors showed that an IMI for indicated prevention has a high likelihood for cost-effectiveness, both from a societal and a public health care perspective ([@bb0130]). After the development of an intervention, the primary running costs are directly related to guidance time.

Previous research on guidance intensity and efficacy led to assume that internet-based mental health interventions without any kind of guidance were less effective than interventions including at least some guidance from a professional ([@bb0355]; [@bb0510]; [@bb0570]). One study examining the role of support in internet-based problem-solving treatment for symptoms of anxiety and/or depression found that participants who received weekly support improved significantly in reducing depression compared to a WCG while participants with no guidance, guidance on demand, or guidance without training showed no significant improvement ([@bb0385]). Results for the reduction of anxiety were less pronounced but still in favor of the weekly support condition. This notion is partly supported by a systematic review ([@bb0035]), identifying 14 articles fulfilling inclusion criteria, which showed superiority of guided internet-based interventions for mental health related problems in comparison to unguided treatment. However, the review and recent emerging evidence also propose that differences in outcomes between guided and unguided interventions are smaller than previously assumed, or might even be non-existent altogether ([@bb0215]; [@bb0395]; [@bb0465]; [@bb0480]).

A reason unguided IMIs might be preferable even when potentially less effective is that they could produce larger effects at a population level with regard to the reduction of disease burden, as many more individuals could be reached at comparable costs. The evaluation of (cost-)effectiveness, therefore, remains an open research question and more studies are needed directly comparing guided and unguided IMIs for mental health related issues ([@bb0085]; [@bb0240]).

Study aims: This study aims at investigating the (cost-)effectiveness of a guided and unguided transdiagnostic individually tailored IMI for the prevention of MDD and AD in a clearly defined subclinical sample. The subclinical sample is defined by including individuals who show detectable symptoms of depression and anxiety indicated by a score of ≥16 on the Center for Epidemiological Studies Depression Scale (CES-D) ([@bb0330]; [@bb0490]) or score of ≥5 on the assessment of the Generalized Anxiety Disorder (GAD-7) ([@bb0575]), and who do not fulfill criteria for a full-blown AD or MDD as assessed in a diagnostic interview.

Specific aims include: 1) to evaluate the efficacy of guided and unguided IMIs to reduce the incidence of full syndrome CMDs compared to TAU, 2) to assess the efficacy of guided and unguided IMIs on symptom severity and other psychological outcomes when compared to TAU, 3) to compare the efficacy of guided and unguided IMIs on the reduction of symptom severity and other secondary continuous outcomes, 4) to assess the cost-effectiveness of guided and unguided IMIs, and lastly 5) to assess and compare the acceptability of guided and unguided IMIs.

2. Materials and methods {#s0010}
========================

2.1. Objectives and hypotheses {#s0015}
------------------------------

We hypothesize 1) that both guided and unguided IMIs are more effective and cost-effective than TAU (no intervention); 2) guided IMIs to show higher effectiveness, lower cost-effectiveness but greater acceptability by the participants than unguided IMIs.

2.2. Participants {#s0020}
-----------------

We will include individuals who...-are at minimum 18 years of age, in the Dutch trial site individuals can participate from the age of 16,-score ≥16 on the Center for Epidemiological Studies Depression Scale (CES-D) ([@bb0330]; [@bb0490]) or score ≥5 on the assessment of the Generalized Anxiety Disorder (GAD-7) ([@bb0575]),-have Internet access and a valid email address,-sufficient language skills in the considered program language in reading and writing,-and are willing to give informed consent.

We will exclude individuals who...-are currently on a waiting list for mental health treatment or have received psychological treatment in the previous 6 months for depression and/or anxiety,-currently fulfill the criteria for a full syndrome MDD or AD according to the Mini International Neuropsychiatric Interview Version 5.0 (Mini) ([@bb0560]),-fulfilled criteria of an MDD or AD in the previous 6 months and showed a main symptom (Dysphoria, Anhedonia) of MDD in the previous 3 weeks (to exclude individuals currently in remission of MDD),-report to have been diagnosed with psychosis, bipolar disorder or experienced dissociative symptoms in the past,-or show a high suicidal risk in the MINI during the diagnostic interview.-Participate in similar studies at the time of inclusion (only in the Netherlands).

### 2.2.1. Recruitment {#s0025}

Participants will be recruited in Germany, Switzerland, Austria, Spain and the Netherlands. They are primarily recruited through cooperating health care insurances via their webpages as well as through members\' magazines. Moreover, participants will also be recruited through an internationally organized mental health care risk assessment in university students (caring university project, WHO World Mental Health international college survey). Participants in the Netherlands are recruited through the latter, as well as additional recruitment strategies, such as flyers and posters on campus sites. The study website provides information about the *ICare Prevent* online training ([icareprevent.com](http://icareprevent.com){#ir0010}), the general study procedure, and details on how to sign up for participation. The trial is open to all individuals fulfilling the inclusion criteria and not restricted to the cooperating health care insurance companies and universities. Recruitment will begin in February 2017. Interested individuals can sign up for participation on the *ICare Prevent* website ([icareprevent.com](http://icareprevent.com){#ir0015}) or associated webpages, or contact the study administration team via email directly (<training@icareprevent.com>) by providing the research team with their email address and a name which can be a pseudonym if desired.

### 2.2.2. Assessment of eligibility and randomization {#s0030}

Individuals who apply for study participation will receive an email with detailed information about the study procedure. Applicants are asked to complete online screening questionnaires that assess the severity of their depression (CES-D ≥ 16) and their anxiety level (GAD-7 ≥ 5). The screening also includes questions on demographical information, assessment of history and current state of mental health, and past and current treatment history. Once the screening is completed and participants fulfill the inclusion and do not fulfill any exclusion criteria, participants receive detailed study information and a consent form. Participants in the Netherlands receive and fill-out the consent form before the screening. They are notified that they can withdraw from the intervention and/or study at any time without any negative consequences. They must sign the consent form and send it back via post or email. Once the signed consent is received, trained interviewers will conduct the diagnostic interviews, and individuals that fulfill the inclusion and none of the exclusion criteria will proceed to complete the baseline questionnaires. As soon as participants have completed all baseline questionnaires, they enter the study and are randomized to one of the three study conditions: guided intervention, unguided intervention, or TAU.

Participants are randomized to either one of the intervention groups (unguided intervention or guided intervention) or TAU in a 1:1:1 ratio. Randomization will be stratified according to trial site (Germany/Switzerland, Spain, and the Netherlands), and presence of subclinical symptoms (three strata: S1, subclinical anxiety; S2, subclinical depression; S3, subclinical anxiety and subclinical depression). A block-randomization algorithm with concealed block length will be used. The generation algorithm and resulting lists are validated by an independent biostatistician not otherwise directly involved in the study. The generation of randomization lists and the randomization of enrolled participants will be performed centrally for all countries by the ICare partner Westfälische-Wilhelms-Universität Münster (Institute of Biostatistics and Clinical Research, Westfälische-Wilhelms-Universität Münster, Germany) not directly involved in the recruitment or active study phase.

During the randomization process, allocation will be concealed from participants, researchers involved in recruitment and study administration, diagnostic assessors and eCoaches. Once randomization has been completed by the independent researcher, the study administration is informed about randomization outcome who inform the participants about the outcome (only whether they receive immediate or delayed access to treatment), and participants in the intervention groups then receive immediate access to the *ICare Prevent* training. The participants in the control group will receive the login data required to complete the training 12 months after randomization.

2.3. Study design {#s0035}
-----------------

This trial will be conducted in compliance with the protocol, the Declaration of Helsinki, and good clinical practice. The trial is registered in the German Clinical Trial Registration (<http://www.drks.de/drks_web/>,DRKS00011099).

All procedures involved in the study will be consistent with the generally accepted standards of ethical practice approved by local ethics committees of each partnering country:-Friedrich-Alexander University Erlangen-Nuremberg ethics committee (144_16 B),-the Ethics Commission of the Canton of Bern (2016--01389),-the Ethics Committee of the University of Valencia (H1476878127646),-and the Medical Ethics Committee of the Vrije Universiteit Amsterdam (2017.131).

Data security/confidentially will be guaranteed; all relevant EU legislation and international texts on privacy will be observed and respected. Regarding regulation at international level, starting from the OECD guidelines including the "Guidelines on the protection of privacy and transborder flow of personal data" (1981) and "Guidelines for the security of information systems" (1991/92), the ICare consortium in particular acknowledges heterogeneity in international data protection jurisdiction.

A three-armed multi-country RCT will be conducted to compare guided and unguided IMIs with TAU. Trial sites are in Germany/Switzerland, the Netherlands, and Spain. Both active conditions are based on the same intervention *ICare Prevent* and differ only with regard to the guidance format (unguided and guided treatment). All intervention arms will have full access to TAU. TAU differs per country and region. In all countries, TAU is likely to be heterogeneous but this is a reflection of clinical practice. We will not interfere with nor manualize TAU. However, to control for potential confounding effects, TAU will be closely monitored by self-report assessments. By this, we mean that information on all types of medical help received during the duration of the study will be collected so that an accurate description of TAU will be available. After the initial screening, assessments will take place at baseline (T1), mid-intervention (after completion of module 5 or 5 weeks after randomization, T2), post-intervention (8 weeks after randomization, T3), at 6 months follow-up (T4), and at 12 months follow-up (T5). See [Table 3](#t0015){ref-type="table"} for a detailed overview of assessments. See [Fig. 1](#f0005){ref-type="fig"} for a detailed overview of the study design.Fig. 1Study Design.Fig. 1

2.4. Intervention {#s0040}
-----------------

The transdiagnostic individual tailored *ICare Prevent* online training aims at reducing depressive complaints and anxieties, reduce associated risk factors, and strengthen protective factors. The training is internet-based and supported by a mobile app. Transdiagnostic elements of the intervention include psychoeducation on etiological and maintaining factors of depressive and anxiety symptoms, and targeting common risk factors. Furthermore, the intervention can be individually tailored to the specific need of the individual as participants can choose to focus on problem solving, recommended for persons with depressive mood, or practice exposition to fear-inducing situations, aimed at individuals suffering from anxieties, and participants can continuously choose to focus on topics of interest throughout the intervention. The transdiagnostic individual tailored approach enables to target both depression and anxieties, but also to tailor the treatment to other individual preferences and risk factors. One main strategy of the intervention, commonly found in internet interventions, is the concept of self-help. To foster self-help techniques, participants are encouraged to integrate and practice newly acquired strategies in daily life through transfer tasks (homework assignments). The intervention builds on adaptions of evidence-based modules from an a range of previous interventions which have shown to be effective in the prevention of MDD ([@bb0125]; [@bb0255]), treatment of depression ([@bb0115]; [@bb0270], [@bb0275]; [@bb0265]; [@bb0475]), and sleeping problems ([@bb0245], [@bb0250]; [@bb0585], [@bb0590]).

The intervention consists of eight modules: addressing needs (session 1), behavioral activation (session 2), psychoeducation (session 3), cognitive restructuring (session 4), problem solving or exposure (session 5 and 6), planning for the future (session 7) and a booster session (session 8) (see [Table 1](#t0005){ref-type="table"} for an overview of the main modules). Participants can choose between two disorder-specific modules in session 5: problem solving (training for participants who want to focus primarily on the reduction of depressive symptoms) and exposure (for participants who want to focus on the reduction of symptoms of anxiety). Another major element is that participants can choose between several elective modules (integrated into sessions 2 to 7) based on individual need and/or preference. The elective modules are directed at rumination & worries, acceptance, relaxation, alcohol & affect regulation, self-worth, perfectionism, appreciation and gratefulness, and sleep (see [Table 2](#t0010){ref-type="table"} for an overview of the elective modules). Each session can be completed in approximately 45 to 60 min. We advise participants to do at least one and a maximum of two sessions per week. Further content can only be accessed once previous sessions are completed. Consequently, the training lasts about 4 to 7 weeks plus one additional booster session 4 weeks after completion of the last session. The booster session aims to help participants transfer acquired strategies into daily life. Sessions consist of texts, testimonials, audios, short educational video clips, and also include interactive elements such as quizzes, exercises, and homework. Participants are also encouraged to keep an online diary at certain intervals of the training which can be accessed either via the web interface or an optional smartphone app. The intervention uses content tailoring, thereby engaging the participant by encouraging them to make real-time choices among various response options, and then providing individualized content based on specific needs or preference. The training is built on responsive web-design and can be completed on any kind of internet-ready device, such as PCs/laptops, smartphones, or tablets. Participants can follow narrated lessons by activating the read-aloud function. Participants can also opt to receive motivational messages and small exercises referred to as Smart Coach. These messages are sent directly to their mobile device. They can choose between a light version (3 messages per day) and an intensive version (5 messages per day). These notifications will support the participants in transferring the exercises of the training into their daily lives (e.g., short relaxation exercises: "Relax your muscles in your hands and arms for 3 seconds now. Follow your breathing and each time you breathe out, relax a little more.").Table 1Content of the ICare Prevent training.Table 1Intervention contentSessionAddressing needs1Behavioral activation2Psychoeducation3Cognitive restructuring4Problem Solving or Exposure5Problem Solving or Exposure6Plan for the future7Booster session8Table 2Content of the *ICare Prevent* elective modules.Table 2Rumination & worries:Dealing with excessive worrying & reducing rumination habitsAcceptance:Acceptance of undesired affective statesRelaxation:Progressive muscle relaxationAlcohol & affect regulation:Reducing affect regulation related alcohol consumptionSelf-worth:Acknowledging and strengthening self-worthPerfectionism:Dealing with perfectionismAppreciation & gratefulness:Practicing mindfulness strategiesSleep:Improving sleep hygiene and practicing sleep restriction to enhance sleep quality

### 2.4.1. Addressing needs (session 1) {#s0045}

In the first session, participants receive an introduction to the training and familiarize with the session content as well as the core elements, such as testimonials, diaries, and videos. Motivation is strengthened by assessing personal treatment motivation, and participants are asked to formulate realistic, individual and concrete goals which can be modified and revised throughout the training. One main focus of the intervention lies on reducing personal incongruence in daily life, by supporting participants to achieve a balance between personal needs and values, and behavior based on the congruence theory by [@bb0310]. Hence, participants are educated on the relationship between personal needs and values, and psychological well-being, and then work on identifying their unfulfilled needs and core values. They are encouraged to plan activities which serve the purpose of strengthening life areas important to them, and progress and difficulties can be documented in the activity diary.

### 2.4.2. Behavioral activation (session 2) {#s0050}

In the second session, participants are presented with strategies on how to deal with difficulties concerning the implementation of planned activities and how to reduce avoidant behaviors. In addition to behavioral activation strategies related to core personal needs and values addressed in session one, they are also introduced to the concept of mood stabilizing reinforcing activities that can be used to overcome lowered mood, and participants are encouraged to plan exercising self-chosen pleasant activities in their daily life.

### 2.4.3. Psychoeducation (session 3) {#s0055}

The participants are provided with psychoeducational information on depression and anxiety, and the multifactorial causes explaining etiology and maintenance. Participants are encouraged to identify symptoms they have previously experienced or are currently dealing with. Information on the different forms of depression and anxiety including diagnosis criteria is provided. To enhance the understanding of the disorders, influencing factors benefitting the development and maintenance of depression and anxiety, risk factors, and the vicious circles of upkeep are explained. After receiving general information, participants can choose throughout the session whether to review detailed information on one of the disorders (depression or anxiety) or work through both. Participants are asked to identify their symptom development and describe the course of their symptomology.

### 2.4.4. Cognitive restructuring (session 4) {#s0060}

In the fourth session, participants receive information on the causal relationship between cognitions and emotions. Participants are introduced to a thought record in which situations are divided into three components: situations, thoughts, and consequences. Participants are given the opportunity to individualize their personal thought records by including personal situations, cognitions, and emotions. The importance of negative emotions is also stated. In the second phase of the thought record, participants are motivated to question the reality basis of their negative thoughts, encouraged to find positive and helpful thoughts, and to generally concentrate on and practice positive thinking habits.

### 2.4.5. Problem solving or exposure (sessions 5 & 6) {#s0065}

Participants can choose whether they wish to work on 1) acquiring and enhancing problem solving skills to reduce depressive symptomology, or 2) practicing exposition to fear-inducing stimuli and situations to reduce feelings of anxiety.

Participants learn the distinction between solvable and unsolvable problems and are asked to assign their own problems to these two categories. They are introduced to the concept of a 6-step problem-solving plan in which they: 1) identify a problem, 2) define a realistic target state, 3) find possible solutions and choose the seemingly best solution, 4) create a detailed solution plan, 5) practice a plan, and 6) verify the implementation success. Participants are expected to practice their plan during the following week in real life situations, and are encouraged to analyze the success or failure of it in the following session. They can also opt to review and adapt their plan in the following session.

Participants who wish to reduce anxieties are introduced to the concept of avoidant and safety behavior, how confrontation of fear can lead to habituation, and practice exposure to fear-inducing situations. Participants are educated on the importance of confronting fears through exposition, what actually happens during exposition, and why it is more effective in the long term perspective for enhancing well-being than avoidance strategies. Participants are asked to identify perceived difficult and fear-inducing situations, and rate their expected feelings of anxiety in relation to these situations. They are introduced to strategies to deal with and work on overcoming their anxiety by exposure to fear-provoking situations. It is recommended to start with less threatening situations and once these seem manageable to work on more severe situations. Participants are introduced to a challenge management protocol, which intends to prepare them for the situations they aim to work through. In the following session, they can evaluate their implementation success, identify personal safety behavior, and focus on facing more challenging situations. Participants are encouraged to create a plan for the upcoming weeks to practice exposition to more fear-inducing situations.

### 2.4.6. Plan for the future (session 7) {#s0070}

In the last training session, participants can review brief summaries of each session. They are asked to reflect on progress concerning their training goals, and to identify mechanisms of the training that helped them. They are also given the opportunity to write a letter to their future selves assuming they have completed four more weeks of practice of acquired strategies. Subsequently they are encouraged to make a plan of specific strategies they want to continue to train in everyday life until the booster session, in order to maintain and generalize acquired strategies.

### 2.4.7. Booster session (session 8) {#s0075}

The participants are invited to complete a booster session four weeks after completion of the seventh session. In this session, they can reflect on their learning experience and personal goal attainment. They are asked to reflect on their current state of mental health, and provided with additional information on support, if needed. Participants can review the letter they wrote to themselves in the last training session, can reformulate their goals and are asked to make plans to implement their intentions in the coming months.

### 2.4.8. Support {#s0080}

#### 2.4.8.1. Guided treatment {#s0085}

During the active intervention phase participants of the guided treatment arm are supported by an eCoach who provides individual manualized feedback after completion of each session. eCoaches will have at least a Bachelor\'s degree in Psychology and have access to supervision when required. Guidance is manualized, eCoaches use preformulated standardized text blocks that are prepared for every lesson. The standardized text blocks are individually adapted to the clients input and overall progress. The eCoaches communicate with participants through the internal messaging function of the platform. Estimated mean time per feedback is 20 min. eCoaches are advised not use \>30 min per individual feedback. Approximately 2.5 h is the total time an eCoach will spend per participant. Session adherence is also monitored, when participants fail to complete a session within 7 days, eCoaches will send out email reminders (after 7, 14, and 21 days). Additionally, after 28 days a reminder will be sent via text message (not in the Netherlands NL). Both personal and automatic reminders have shown to improve adherence to self-guided health promotion and behavior change interventions ([@bb0295]; [@bb0605]).

#### 2.4.8.2. Unguided treatment {#s0090}

Participants of the unguided treatment arm do not receive any individualized feedback, however, after completion of a session, they will receive encouraging standardized messages automatically sent through the training platform. Session adherence is monitored and participants are also provided with messages based on non-adherence. Should participants fail to complete a session within 7 days, they will receive standardized email reminders (after 7, 14, 21 days) by the study administration team encouraging them to continue working on the current module. If participants fail to respond within 28 days, they will receive a reminder via text message (not in NL).

All study participants can contact a support email address (<support@icareprevent.com>) in case of any technical difficulties with the training or the assessments.

2.5. Assessment and data management {#s0095}
-----------------------------------

Data management and monitoring will be provided by the Institute of Biostatistics and Clinical Research (Westfälische Wilhelms-Universität Münster) for the whole ICare consortium in order to maintain comparable high quality in the conduct of the ICare research projects in trial planning, data management, online monitoring, and analysis.

Self-reports and observer-based assessments will take place at screening (T0), baseline (T1), mid-intervention (T2, after completion of module 5 or 5 weeks after randomization), post-intervention (T3, 8 weeks after randomization), and at 6- (T4) and 12-month follow-ups (T5). Observer-based assessments from clinical diagnostic interviews will be carried out via telephone. Self-report data will be collected using a secured online-based assessment system (AES, 256-bit encrypted).

### 2.5.1. Observer-based assessments {#s0100}

Diagnostic clinical interviews will be conducted at baseline, at post-intervention, and at 6- and 12-month follow-up. The interviews consist of an adaption of the MINI focusing on depression and any anxiety disorder (Mini 5.0) ([@bb0560]), the Quick Item Inventory of Depressive Symptomatology clinician rating (QIDS-C) ([@bb0540]), and structured interview of the Hamilton Anxiety Rating Scale (SIGH-A) ([@bb0325]; [@bb0555]). The MINI will not be assessed at post-intervention.

All clinical interviews will be conducted by trained master psychology students or experienced psychotherapists who are blind to treatment condition. The interviews will be recorded and approximately 10% of the cases will be assessed by another rater to examine interrater reliability. Disagreement shall be solved by discussion and the agreed rating will be used for analysis. If this is not possible, the assessment will be rated by an experienced psychotherapist (gold standard) and this rating will be used for analysis. Interrater reliability will be reported for each trial site (Germany/Switzerland, Spain and the Netherlands) individually. Measures to assure blinding include: (a) explanation to the participant the importance of keeping the assessors blinded to randomization status; (b) verbal reminder to the participant before each assessment; and (c) documentation after each assessment, whether the interviewer is still blind to treatment condition. In case of evidence for blinding break down, the interviewer will be changed to the next outcome interview. The interviewers will be asked to guess each participant\'s randomization status. These guesses will be compared with the actual status. Cohen\'s kappa will be computed to clarify whether hit rates differ from what can be expected from chance.

2.6. Outcomes {#s0105}
-------------

### 2.6.1. Primary outcome {#s0110}

Primary outcome will be time to CMD onset (any anxiety/depression disorder) in guided and unguided IMI compared to TAU within a 12 months follow-up period assessed by the MINI 5.0 ([@bb0560]). The Mini will be assessed at baseline, 6 months follow-up (FU) and 12 months FU. The frequency of outcome interviews allows for a temporal precision of onset of CMD within the inspected timeframe. The exact time to CMD onset (given in weeks since randomization) will be assessed as accurately as possible using the Life Chart method developed by [@bb9000] in order to reduce a potential recall bias. In this method, age- and calendar-linked personal landmarks are used to assess the time sequence of i.e. depressive symptomatology and life events in parallel. During the interview the first day of an episode will be established. If the exact day could not be established, the closest week (month) will be defined and the mid-point of that week (month) will be used.

### 2.6.2. Secondary outcomes {#s0115}

#### 2.6.2.1. Observer-based {#s0120}

Observer-rated depressive symptom severity is assessed by clinician ratings by the QIDS-C ([@bb0540]) at baseline, 8 weeks post-intervention, at 6- and 12-month follow-up. It encompasses the following nine criteria in 16 items: sleep, sad mood, appetite/weight, concentration/decision making, self-view, thoughts of death or suicide, general interest, energy level, and restlessness/agitation. Each item is answered on a scale from 0 to 3, and total scores range from 0 to 27 ([@bb0540]). A meta-analysis showed Cronbach\'s alpha (α) was found to be acceptable (α = 0.69--0.89) ([@bb0500]).

Observer rated anxiety symptom severity will be assessed using the SIGH-A ([@bb0555]) at baseline, 8 weeks post-intervention, at 6- and 12-month follow-up to assess the severity of anxiety. It consists of 14 items rated from 0 to 4, 4 being the most severe. The score is summed to receive an overall rating of anxiety severity ranging from 0 to 56. Test-retest reliability of the SIGH-A was 0.89 ([@bb0555]).

#### 2.6.2.2. Self-report {#s0125}

The complete list of self-report measures and measurement time points are shown in [Table 3](#t0015){ref-type="table"}.Table 3Overview study self-report assessments.Table 3ConstructQuestionnaireT0T1T2T3T4T5**Demographics**Socio-demographic data (SozDemo)✔----------**Psychopathology**\
*Mental health*Mental health (PG)✔----------Psychopathology\
*Depression*Center for Epidemiological Studies Depression Scale - Short Version (CES-D)[⁎](#tf0005){ref-type="table-fn"}✔--✔✔✔✔Psychopathology\
*Anxiety*General Anxiety Disorder Measurement (GAD-7)✔--✔✔✔✔Psychopathology\
*Depression*Patient Health Questionnaire (PHQ-9)--✔✔✔✔✔Psychopathology\
*Alcohol abuse*The Alcohol Use Disorders Identification Test (AUDIT-C)--✔✔✔✔✔**Quality of life**\
*Wellbeing*WHO-Five Wellbeing Index (WHO-5)--✔--✔✔✔Quality of lifeEuroQol (EQ-5D)--✔--✔✔✔Quality of lifeAssessment Quality of Life (AQoL-8D)--✔--✔✔✔Quality of life\
*Health economic evaluation*Client Service Receipt Inventory (CSRI)--✔----✔✔**Training**\
*Expectancy*Credibility/Expectancy Questionnaire (CEQ)--✔--------Training\
*Negative treatment effects*Inventory to assess negative effects of psychotherapy (INEP)------✔----Training\
*Program evaluation*(Based on) Client Satisfaction Questionnaire (CSQ-8)----✔✔----Training\
*Attitudes toward help*Attitudes Toward Seeking Professional Help (ATSPPHS)[⁎](#tf0005){ref-type="table-fn"}--✔--✔----Training\
*Supportive accountability*Supporting Accountability (SA)----✔------Training\
*Treatment Satisfaction*(adaption of) Working Alliance Inventory SR (WAI-SR)----✔------**Risk factors**\
*Risk factors questionnaire*Risk Factor Questionnaire (developed by ICare Prevent team) (RF)--✔--------Risk factor\
*Worry*Penn State Worry Questionnaire -- Ultra Brief (PSWQ-3)--✔--✔✔✔Risk factor\
*Sleep*Pittsburgh Sleep Quality Index (PSQI)--✔--✔✔✔Risk factor\
*Self*-*esteem*Rosenberg Self Esteem Scale (RSES)--✔✔------Risk factor\
*Resilience*Connor-Davidson Resilience Scale (CD-RISC)--✔✔✔✔✔**Other**\
*Emotion regulation*Subscales of emotion regulation scale questionnaire (SEK-15)--✔--✔✔✔Other\
*Incongruence*Incongruence questionnaire (short version) (INK-K)--✔✔✔✔✔Other\
*Personality*Big Five Inventory (BFI-10)--✔--------Other\
*Self*-*regulation*Self-Regulation Scale (SSRQ)[⁎](#tf0005){ref-type="table-fn"}--✔--------Other\
*Behavioral activation*The Behavioral Activation for Depression Scale (BADS-FS-9)--✔--✔✔✔OtherDrop-Out Reasons (developed by ICare Prevent team) (DG)------✔----OtherOther help (developed by ICare Prevent team) (INH)------✔----[^1][^2]

#### 2.6.2.3. Psychopathology {#s0130}

Self-reported depressive symptoms will be measured with the Center for Epidemiological Studies Depression Scale (CES-D) ([@bb0490]). This frequently used self-report instrument consists of 20 items that are answered on a four-point Likert scale referring to the previous week. Total scores range from 0 to 60. The internal consistency of this measure has been found to be excellent (α = 0.95) ([@bb0415]). Depressive symptoms are also measured by the Patient Health Questionnaire (PHQ-9) ([@bb0400]) and consist of 9 items. Each item covers one of the nine DSM-IV criteria for the diagnosis of a major depression. This instrument has a high internal reliability (α = 0.89) and also test-retest reliability with 0.84 ([@bb0420]; [@bb0440]; [@bb0575]), and shown to have a good interformat reliability to paper, when delivered online ([@bb0285]).

The generalized anxiety disorder measurement (GAD-7) ([@bb0575]) is used to assess GAD and symptom severity. It consists of 7 items answered from 0 (not at all) to 3 (nearly every day). It possesses excellent internal consistency (α = 0.92) and good test-retest reliability (intraclass correlation (ICC) = 0.83) ([@bb0425]; [@bb0575]).

Substance abuse will be assessed by a 3 item alcohol screen (AUDIT-C) ([@bb0135]). Each item is answered on a 5-point Likert scale and the total score ranges from 0 to 12. This measurement has acceptable psychometric properties (α = 0.61, ICC = 0.89) ([@bb0095]; [@bb0230]).

Worry will be assessed by the 3 item Penn State worry questionnaire ultra brief (PSWQ-3; range 0--18, α = 0.85) ([@bb0065]; [@bb0460])

Sleep quality will be assessed by the 1 item subscale of the Pittsburgh sleep quality index (PSQI) ([@bb0140]), answered on a 4-point Likert scale. Psychometric properties are acceptable (α = 0.74, ICC = 0.86) ([@bb0470]; [@bb0505])

#### 2.6.2.4. Quality of life {#s0135}

To measure quality of life we will use the Assessment of Quality of Life Instrument (AQoL-8D) ([@bb0520]; [@bb0515]), which consists of 35 items. They entail eight dimensions: independent living (α = 0.9, ICC = 0.86), pain (α = 0.85, ICC = 0.86), senses (α = 0.69, ICC = 0.51), mental health (α = 0.84, ICC = 0.89), happiness (α = 0.85, ICC = 0.90), coping (α = 0.80, ICC = 0.79), relationships (α = 0.73, ICC = 0.88), self-worth (α = 0.85, ICC = 0.81) ([@bb0520]). Psychometrics properties are, therefore, acceptable.

Additionally, the EuroQol (Group, 1990), consisting of five dimensions (EQ-5D-5 L) and a visual analogue scale for self-rated health state, will be applied to measure health-related quality of life. The dimensions consist of mobility, self-care, usual activities, pain/discomfort and are answered on a 5-point scale from 1 (no problems) to 5 (severe problems). Psychometric properties are acceptable (α = 0.7, ICC = 0.64) ([@bb0380]; [@bb0430]).

The AQoL-8D and EQ-5D-5 L ratings will be used in the economic evaluation.

#### 2.6.2.5. Well-being {#s0140}

Well-being will be assessed by the 5-item WHO-5 Well-Being Index (WHO-5) ([@bb0635]) answered on a 0 through 5 scale, and scores range from 0 to 30 (α = 0.82) ([@bb0210]).

### 2.6.3. Health economic evaluation {#s0145}

Key to the cost-effectiveness and cost-utility analyses is information on the impact of the intervention on publicly funded services and the wider society. Individuals\' use of services and supports will be recorded on an adapted client service receipt inventory (CSRI) ([@bb0050]) alongside wider societal impacts such as productivity loss. Unit costs will be estimated for each service and support used following well-established theory-driven methods and multiplied by the use made be each individual to obtain a cost per person ([@bb0045]). Costs will be expressed in the same currency across countries using OECD purchasing power parities data

### 2.6.4. Training and acceptability {#s0150}

User satisfaction will be assessed by a questionnaire based on the Client Satisfaction Questionnaire (CSQ-8) ([@bb0020]), adapted to assess user satisfaction in online interventions ([@bb0090]). Global client satisfaction with internet-based training is measured by 8 items. Previous research indicated good psychometric properties (α = 0.84--0.97) ([@bb0445]).

Other measures related to the training include participant expectation (CEQ) ([@bb0080]; [@bb0220]), satisfaction with treatment, an adaption of the Working Alliance Inventory (WAI) ([@bb0340]), negative effects of the treatment (INEP) ([@bb0410]), and attitudes toward seeking professional psychological help (ATSPPH) ([@bb0290]; [@bb0580]). Lastly, the occurrence of any negative effects will be identified as in Rozental et al. at the 12 months follow-up ([@bb0535]).

### 2.6.5. Response {#s0155}

To determine the numbers of participants achieving a reliable positive outcome, we will code participants as responders or non-responders according to the widely used reliable change index (RCI) ([@bb0350]) after participation in the intervention. Participants will be considered responders when they display an RCI score of above 1.96.

### 2.6.6. Other assessments {#s0160}

Other assessments include demographics (e.g., age, gender, occupation, level of education etc.), current and previous mental health issues, current and previous experience with psychotherapy, personality dimensions measured by the ultra-short version of the Big Five Inventory (BFI-10) ([@bb0495]), behavioral activation (BADS-FS) ([@bb0300]; [@bb0365]; [@bb0435]), self-regulation (SSRQ) ([@bb0145]), self-esteem (RSES) ([@bb0530]), resilience (CD-RISC) ([@bb0175]), motivation (TEQ) ([@bb0545]), various emotion regulation skills (subscales comprehension, acceptance, and emotional self-support by the German Emotion Regulation Scale Questionnaire, ERSQ-27, ERSQ-ES-GD) ([@bb0060]; [@bb0235]).

Additionally, risk factors for the onset of depression and anxiety, e.g. aspects of physical health, traumatic childhood and life events, family psychopathology, social environment, are assessed at baseline in order to investigate moderators of treatment outcome.

Adherence will be tracked by the system based on session completion.

### 2.6.7. Qualitative interviews {#s0165}

At least 10 participants with predominantly subclinical depression and anxiety symptoms that have been randomized to the intervention condition who have completed the intervention or who dropped out, will be asked to participate in qualitative interviews. The qualitative interviews aim at collecting subjective information on factors regarding training efficacy and adherence. These type of interviews can help improve IMIs with the goal of heightening engagement. Aspects assessed by the interview will include a) participants hope of improvement and expectations, b) perceived usefulness of the training, c) reasons for treatment success and failure, d) reasons for training adherence and non-adherence, e) usability and layout, f) quality and content of the intervention and received guidance, and g) overall strengths and limitations of the training. The analysis of the interviews is based on the qualitative content analysis by Mayring and Kuckarts ([@bb0405]; [@bb0455]).

2.7. Statistical methods {#s0170}
------------------------

Data will be analyzed on an intention-to-treat basis including all participants who will be randomly assigned to conditions. Additionally, a per protocol analysis (PPA) will be conducted including only participants satisfying treatment protocol and assessments.

Time to onset of CMD between unguided and guided ICare Prevent and TAU will be analyzed by a two-sided log rank tests. We will test the two primary statistical hypotheses, i.e. (i) guided training vs. TAU and (ii) unguided training vs. TAU. The emerging multiple testing problem will be considered appropriately, by using a Bonferroni adjustment of local significance levels. Comparing survival curves instead of just onset rates allows a more precise estimation of the intervention effects and also increases power, thereby allowing for the detection of smaller effects. Missing data will be handled by censoring.

For differences in the change of depression and anxiety symptom severity multi-level mixed models regression analyses will be used. Depending on the distribution of data in the various outcome parameters we will choose either linear models (for normally distributed data) or negative binomial models (for left-skewed data). Each model includes assessment time as a predictor. The influence of potential predictive factors will be investigated by adding corresponding interaction terms to the model. All analysis will first be adjusted for country, type of subclinical symptoms, baseline symptom severity, history of mental health disorder, previous treatment experience and potential comorbid disorders. Missing data will be handled using multiple imputation.

We will also conduct a number of pre-planned exploratory subgroup analyses such as a) per country, b) per disorder, c) with/without comorbidity (depression & any anxiety; depression & alcohol abuse; any anxiety & alcohol abuse; combination of different specific anxiety disorder symptoms anxiety comorbidities). d) Moreover, we will create a multivariate risk prediction algorithm based on baseline risk factors and in which we will test the assumption that individuals with high vs. low predicted risk show a differential treatment effect.

For all analyses on continuous measures, Cohen\'s d ([@bb0170]) will be calculated by standardizing the differences between baseline and follow-up scores by the pooled standard deviation of the baselines scores. The response rates will be compared across conditions with the help of contingency tables and Chi-Squared tests. The global significance level of the two null hypotheses tested within the primary analysis of the trial will be maintained by Bonferroni correction. Thus, the local significance levels are 2.5%. For the explorative analysis of the data, the significance levels will be set to 5%. Thus, *p* ≤ 0.05 will indicate the rejection of the respective null-hypothesis. The number needed-to-treat (NNT) with *ICare Prevent* (guided and unguided) to prevent one case of a CMD, respectively to achieve one response as compared to the control group, will be calculated.

The health-economic evaluation will involve a combination of a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA). The economic evaluation will be performed from a societal perspective (all relevant costs) and public sector costs with a time horizon of 12 months. In the CEA, the incremental cost-effectiveness ratio (ICER) will be expressed as the incremental costs per additional disorder free participant. In the CUA, the ICER will be expressed as incremental costs per quality-adjusted life year gained (QALY) as based on the EQ-5D-5 L. Bootstrapping (5000 times) will be used to quantify the uncertainty around the ICER. The bootstrapped ICERs will be plotted on a cost-effectiveness plane where the horizontal axis reflects differences in effects and the vertical axis differences in costs. The bootstrapped ICERs will also be shown in a cost-effective acceptability curve disclosing the probability that the intervention is cost-effective for a range of willingness-to-pay ceilings. To test the robustness of the base-case findings, a multi-way sensitivity analysis will be conducted. Several assumptions made in the base-case scenario (eg. QALYs based EQ-5D instead of the AQoL-8D) will be changed to assess their impact on the ICER.

The statistical analysis of the primary and secondary outcomes will be described in a statistical analysis plan that will be signed by the study committee and the responsible statistician.

2.8. Sample size calculation {#s0175}
----------------------------

In primary analysis we aim to explore the effects of the intervention on time to disorder onset. Based on meta-analytic evidence on the prevention of depression ([@bb0610]) and randomized trials on combined prevention of depression and anxiety ([@bb0620]), we expect a mean 12-month survival rate (i.e., no disorder onset) in the control group of 75% (25% incidence rate), and 85% (15% incidence rate) in the active conditions, which translate in an absolute risk reduction of 10% and a relative risk reduction of 40%. This is a more conservative estimation than 50% relative risk reduction found in the only trial that has to the best of our knowledge been conducted on the combined indicated prevention of depression and anxiety. To detect such a difference between the active conditions and the control condition with a power of 80% and a significance level of 0.05, 254 participants are needed per group (762 in total). Accounting for 20% drop-out, 954 participants in total need to be recruited (*n* = 363 per group).

Based on the mean results from studies evaluating interventions aimed at the indicated prevention of a CMD ([@bb0005]; [@bb0165]; [@bb0205]; [@bb0565]; [@bb0620]; [@bb0630]) we expect an effect of d = 0.35 ([@bb0190]); difference in the reduction in secondary outcome depression severity between the active groups and the control group. So far evidence for internet-based interventions for subclinical symptoms of anxiety is lacking. Meta analytic evidence for internet interventions targeting anxiety disorders indicates an effect of d = 0.90 for internet-based guided self-help treatments and d = 0.58 for interventions without guidance. Given that the present trial targets individuals with subclinical symptoms with less room for improvement, much lower effects can be expected. Hence, we expect an effect size of d = 0.30.

3. Discussion {#s0180}
=============

Depression and anxiety disorders are greatly prevalent globally and highly comorbid, associated with a decline of quality of life, and linked to substantial economic costs. IMIs could be an attractive, efficient and cost-effective approach to prevent the development of CMDs, by reducing the onset probability of full syndrome CMDs, and targeted at at-risk population transdiagnostic IMIs could help reduce overall disease burden.

To date, few RCTs have been conducted on the prevention of CMDs, and data for transdiagnostic treatment protocols are scarce. A remaining open research question is whether guided or unguided interventions are more cost-effective when implemented on a large scale. After the development of internet-based interventions, the most prominent cost factor is substantially linked to guidance time, and this relationship has not yet been examined in the context of interventions aimed to prevent the incidence of CMDs.

Overall, the present study will be the first to provide evidence for the efficacy and cost-effectiveness of transdiagnostic preventive interventions and provide valuable information on the optimal trade-off between treatment outcome and economical costs.

The present study has several strengths, including the strong methodology of a randomized controlled design with the direct comparison of two active conditions. The assessments include diagnostic outcome interviews as an objective addition to the self-report measurements. Also, there is an appropriate statistical analyses plan and missing data will be handled with state of the art methods. The treatment protocol is transdiagnostic and individual tailored adding to empirical evidence of treatment options targeting a heterogeneous at-risk group. Lastly, the online training is technically advanced as it relies upon content tailoring which allows the participant to make real-time choices which trigger different content based on preference or need.

This study also has some limitations. First, as the study is powered to detect differences between the active groups compared to the TAU group in the primary outcome onset of CMDs, the sample size will be insufficient to draw reliable conclusions on the differential effectiveness of guided vs. unguided IMIs regarding disorder onset. It will remain unclear which participants are likely not to profit from unguided treatment but would potentially profit from guided IMIs. Second, although pooling data from the four participating countries increases the feasibility of reaching the necessary sample size, differences between participants of the different trial sites need to be considered when interpreting the results which could contain larger variance than if conducted solely in one trial site. However, as the study is embedded in the ICare consortium whose goal it is to implement, to disseminate, and to increase acceptability of internet-based mental health interventions across Europe, it is a necessary risk and will also provide valuable information on the overall effectiveness of IMIs for the prevention of CMD in heterogeneous settings in Europe. Third, assessments take place only at post-intervention and follow-up time points; there will be no ambulatory assessment. Therefore, the results will have to be interpreted in relation to these predefined time points. As the intervention is time-consuming in itself and the assessments can be tedious, it was decided not to burden participants any further and possibly risk drop-out with weekly or even daily assessments, and the diagnostic interviews allow for temporal precision determining onset. And lastly, the study has an elaborate screening process. This poses the risk that highly motivated individuals will be more likely to participate in the intervention. In future, interventions must be implemented with low threshold access, in order to estimate the effects when delivered under routine care conditions.

4. Conclusion {#s0185}
=============

To overcome the gap between the need for economical effective strategies for preventing mental health disorders and evidence-based treatment availability, (cost-)effective, low-threshold interventions, accessible to as many people as possible, are needed. Internet- and mobile-based mental health interventions are a promising strategy to overcome some of the limitations of face-to-face mental health interventions. This study will enhance the evidence-base for IMIs and provide information on the differential efficacy, and cost-effectiveness of two guidance forms of *ICare Prevent*.

Trial status {#s0190}
============

The first participants were enrolled in the study on February 1, 2017 Follow-up assessments for the remaining patients are expected to be completed by September 1, 2019.
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[^1]: T0 = screening, T1 = baseline, T2 = 5 weeks after randomization, T3 = post-intervention, 8 weeks after randomization, T4 = 6-month follow-up, T5 = 12-month follow-up.

[^2]: Trial site Netherlands will assess the CES-D only at screening and will not assess ATSPPHS, SSRQ and SEK, participation will be optional in the risk factor questionnaire.
